vs
MID PENN BANCORP INC（MPB）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
MID PENN BANCORP INC的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.7倍（$62.0M vs $35.5M），MID PENN BANCORP INC净利率更高（31.4% vs -304.2%，领先335.6%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 30.8%），MID PENN BANCORP INC自由现金流更多（$71.8M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 21.1%）
该资料实际介绍的是1973年成立于新泽西州切里希尔的商业银行，该银行在2007年被多伦多道明银行收购，并入其旗下的TD Banknorth，之后TD Banknorth统一更名为TD银行。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
MPB vs RXRX — 直观对比
营收规模更大
MPB
是对方的1.7倍
$35.5M
营收增速更快
RXRX
高出651.0%
30.8%
净利率更高
MPB
高出335.6%
-304.2%
自由现金流更多
MPB
多$119.1M
$-47.3M
两年增速更快
RXRX
近两年复合增速
21.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $62.0M | $35.5M |
| 净利润 | $19.4M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 43.6% | -304.8% |
| 净利率 | 31.4% | -304.2% |
| 营收同比 | 30.8% | 681.7% |
| 净利润同比 | 47.0% | 39.6% |
| 每股收益（稀释后） | $0.83 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MPBRXRX
| Q4 25 | $62.0M | $35.5M | ||
| Q3 25 | $61.8M | $5.2M | ||
| Q2 25 | $54.3M | $19.2M | ||
| Q1 25 | $47.7M | $14.7M | ||
| Q4 24 | $47.4M | $4.5M | ||
| Q3 24 | $45.3M | $26.1M | ||
| Q2 24 | $44.1M | $14.4M | ||
| Q1 24 | $42.3M | $13.8M |
净利润MPBRXRX
| Q4 25 | $19.4M | $-108.1M | ||
| Q3 25 | $18.3M | $-162.3M | ||
| Q2 25 | $4.8M | $-171.9M | ||
| Q1 25 | $13.7M | $-202.5M | ||
| Q4 24 | $13.2M | $-178.9M | ||
| Q3 24 | $12.3M | $-95.8M | ||
| Q2 24 | $11.8M | $-97.5M | ||
| Q1 24 | $12.1M | $-91.4M |
毛利率MPBRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率MPBRXRX
| Q4 25 | 43.6% | -304.8% | ||
| Q3 25 | 39.3% | -3327.6% | ||
| Q2 25 | 7.9% | -916.8% | ||
| Q1 25 | 35.2% | -1297.9% | ||
| Q4 24 | 34.1% | -4042.4% | ||
| Q3 24 | 32.8% | -377.1% | ||
| Q2 24 | 32.4% | -697.4% | ||
| Q1 24 | 34.8% | -698.4% |
净利率MPBRXRX
| Q4 25 | 31.4% | -304.2% | ||
| Q3 25 | 29.6% | -3135.3% | ||
| Q2 25 | 8.8% | -894.2% | ||
| Q1 25 | 28.8% | -1373.3% | ||
| Q4 24 | 27.9% | -3935.5% | ||
| Q3 24 | 27.1% | -367.5% | ||
| Q2 24 | 26.7% | -676.6% | ||
| Q1 24 | 28.7% | -662.4% |
每股收益（稀释后）MPBRXRX
| Q4 25 | $0.83 | $-0.17 | ||
| Q3 25 | $0.79 | $-0.36 | ||
| Q2 25 | $0.22 | $-0.41 | ||
| Q1 25 | $0.71 | $-0.50 | ||
| Q4 24 | $0.72 | $-0.56 | ||
| Q3 24 | $0.74 | $-0.34 | ||
| Q2 24 | $0.71 | $-0.40 | ||
| Q1 24 | $0.73 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $814.1M | $1.1B |
| 总资产 | $6.1B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资MPBRXRX
| Q4 25 | — | $743.3M | ||
| Q3 25 | — | $659.8M | ||
| Q2 25 | — | $525.1M | ||
| Q1 25 | — | $500.5M | ||
| Q4 24 | — | $594.4M | ||
| Q3 24 | — | $427.6M | ||
| Q2 24 | — | $474.3M | ||
| Q1 24 | — | $296.3M |
总债务MPBRXRX
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益MPBRXRX
| Q4 25 | $814.1M | $1.1B | ||
| Q3 25 | $796.3M | $1.0B | ||
| Q2 25 | $775.7M | $919.1M | ||
| Q1 25 | $667.9M | $933.9M | ||
| Q4 24 | $655.0M | $1.0B | ||
| Q3 24 | $573.1M | $524.6M | ||
| Q2 24 | $559.7M | $584.4M | ||
| Q1 24 | $551.0M | $401.2M |
总资产MPBRXRX
| Q4 25 | $6.1B | $1.5B | ||
| Q3 25 | $6.3B | $1.4B | ||
| Q2 25 | $6.4B | $1.3B | ||
| Q1 25 | $5.5B | $1.3B | ||
| Q4 24 | $5.5B | $1.4B | ||
| Q3 24 | $5.5B | $726.5M | ||
| Q2 24 | $5.4B | $775.9M | ||
| Q1 24 | $5.3B | $557.8M |
负债/权益比MPBRXRX
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $80.0M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $71.8M | $-47.3M |
| 自由现金流率自由现金流/营收 | 115.8% | -133.1% |
| 资本支出强度资本支出/营收 | 13.3% | 3.5% |
| 现金转化率经营现金流/净利润 | 4.12× | — |
| 过去12个月自由现金流最近4个季度 | $132.1M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流MPBRXRX
| Q4 25 | $80.0M | $-46.1M | ||
| Q3 25 | $26.3M | $-117.4M | ||
| Q2 25 | $29.0M | $-76.4M | ||
| Q1 25 | $11.5M | $-132.0M | ||
| Q4 24 | $51.4M | $-115.4M | ||
| Q3 24 | $16.9M | $-59.2M | ||
| Q2 24 | $18.0M | $-82.2M | ||
| Q1 24 | $12.4M | $-102.3M |
自由现金流MPBRXRX
| Q4 25 | $71.8M | $-47.3M | ||
| Q3 25 | $24.3M | $-117.6M | ||
| Q2 25 | $27.2M | $-79.6M | ||
| Q1 25 | $8.8M | $-133.8M | ||
| Q4 24 | $44.5M | $-116.7M | ||
| Q3 24 | $16.8M | $-63.8M | ||
| Q2 24 | $17.7M | $-83.4M | ||
| Q1 24 | $12.1M | $-109.0M |
自由现金流率MPBRXRX
| Q4 25 | 115.8% | -133.1% | ||
| Q3 25 | 39.4% | -2272.5% | ||
| Q2 25 | 50.1% | -413.9% | ||
| Q1 25 | 18.4% | -907.4% | ||
| Q4 24 | 93.8% | -2567.7% | ||
| Q3 24 | 37.1% | -244.6% | ||
| Q2 24 | 40.2% | -578.5% | ||
| Q1 24 | 28.5% | -789.9% |
资本支出强度MPBRXRX
| Q4 25 | 13.3% | 3.5% | ||
| Q3 25 | 3.1% | 4.7% | ||
| Q2 25 | 3.2% | 16.4% | ||
| Q1 25 | 5.7% | 12.4% | ||
| Q4 24 | 14.6% | 28.6% | ||
| Q3 24 | 0.0% | 17.5% | ||
| Q2 24 | 0.7% | 8.2% | ||
| Q1 24 | 0.8% | 48.2% |
现金转化率MPBRXRX
| Q4 25 | 4.12× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 6.08× | — | ||
| Q1 25 | 0.84× | — | ||
| Q4 24 | 3.88× | — | ||
| Q3 24 | 1.37× | — | ||
| Q2 24 | 1.53× | — | ||
| Q1 24 | 1.02× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
